Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11693205 | 0.92 | GAA (0.53) | ACEGAARAB9ACTSLHCRTR2 | |
| SCHEMBL10465688 | 0.92 | ACE (0.57) | ACEGAARAB9ASMN1; SMN2CTSL | |
| SCHEMBL7814592 | 0.88 | FPR2 (0.63) | ACESMN1; SMN2LDHAHCRTR2FPR2 | |
| SCHEMBL8412092 | 0.88 | FPR2 (0.63) | ACESMN1; SMN2LDHAHCRTR2FPR2 | |
| SCHEMBL10449482 | 0.88 | FPR2 (0.63) | ACESMN1; SMN2LDHAHCRTR2FPR2 | |
| SCHEMBL3883617 | 0.86 | GAA (0.49) | GAARAB9ASMN1; SMN2LDHAALDH1A1 | |
| SCHEMBL3932008 | 0.84 | GAA (0.67) | ACEGAARAB9ACTSLPTPN1 | |
| SCHEMBL3932010 | 0.84 | GAA (0.67) | ACEGAARAB9ACTSLPTPN1 | |
| SCHEMBL28790851 | 0.84 | CTSL (0.71) | ACEGAARAB9ACTSLALDH1A1 | |
| SCHEMBL3927028 | 0.84 | CTSL (0.71) | ACEGAARAB9ACTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550475-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550476-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070004739-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004740-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004740-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | ACE 75/4885GAA 495/4885RAB9A 1574/4885 |
| US-20070010521-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | ACE 75/4885GAA 495/4885RAB9A 1574/4885 |
| US-20070004739-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | ACE 75/4885GAA 495/4885RAB9A 1574/4885 |
| US-20040204418-A1 | Fused-polycyclic compounds | PDE4A, PDE4B, PDE3B | ACE 102/4885GAA 755/4885RAB9A 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.